NCT03634319终止不适用
Early Evaluation of the Brown Glaucoma Implant in Patients Refractory to Drug Therapy in the European Union
MicroOptx3 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2018年6月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 10
- 试验地点
- 3
- 主要终点
- Reduction in IOP
研究概览
简要总结
This is prospective, non-randomized, single-arm study to assess the safety and effectiveness of lowering intraocular pressure with the Beacon Aqueous Microshunt. A total of 65 subjects will be enrolled at five centers. The primary endpoint will be assessed at 12 month follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 22 years and older.
- •Diagnosed with mild, moderate or severe open-angle glaucoma (OAG).
- •Best corrected vision acuity 20/25 or worse in the study eye.
- •Inadequate medical control of IOP, or target IOP not reached with intraocular pressure in the study eye greater than or equal to 20 mmHg.
- •At least two contiguous clock hours of intact conjunctiva near the limbus between clock hours of 09:00 and 03:00 in the study eye.
- •Adequate space in the anterior chamber of the study eye sufficient to support implant with the BAM, defined as two contiguous clock hours of scleral spur visualization via gonioscopy, without compression, in the superior 180 degrees of the anterior angle.
- •Any IOP-lowering medications should be stabilized at least 30 days prior to baseline measurements.
- •Able and willing to comply with protocol requirements.
- •Able to understand and sign the Informed Consent form.
排除标准
- •Active Neovascular Glaucoma in the study eye.
- •Pigmentary Glaucoma in the study eye.
- •Pseudoexfoliative Glaucoma in the study eye.
- •Any eye disease associated with the formation of free-floating material or tissue in the anterior chamber of the eye.
- •Corneal conditions in the study eye that may inhibit normal incisional healing (e.g. Fuch's dystrophy) or impair visualization of the implant inside the anterior chamber.
- •Anticipated need for ocular surgery within one year in the study eye.
- •Contact lens use in the study eye.
- •Clinically significant inflammation or infection in the study eye within 60 days prior to the preoperative visit (e.g., blepharitis, conjunctivitis, keratitis, uveitis, herpes simplex infection) or any systemic infection. For purposes of this study, clinically significant is considered any such condition requiring prescription therapy.
- •Other clinical conditions:
- •Poorly controlled diabetes (Type I or Type II) as determined by HbA1c >
- •Cancer requiring treatment during the duration of the study.
- •Any drugs (e.g.: immunosuppressive drugs) or co- morbidity that might inhibit wound healing.
- •Participation in any other clinical trial during participation in this trial.
- •Life expectancy <1 year.
- •Clinically significant macular degeneration in the study eye.
- •Patients who have undergone surgery in the trial eye within the last 6 months.
- •Planned combined cataract surgery.
- •If both eyes of a prospective trial participant are eligible, the eye with the highest intraocular pressure will be selected for implant.
结局指标
主要结局
Reduction in IOP
时间窗: 12 Months
Overall responder rate, with responder defined as a subject with a diurnal intra-ocular pressure equal to or lower than the individually pre-determined target IOP.
Adverse Event Rate
时间窗: 12 Months
Rate of all AEs
次要结局
- Mean Change from Baseline in IOP(12 Months)
- Responder Rate for 20% reduction(12 Months)
- Reduction in IOP lowering medication(12 Months)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
不适用
Early Feasibility Study of the Brown Glaucoma Implant in Patients With Severe Visual Impairment or No Light PerceivedGlaucomaNCT03469297MicroOptx8
尚未招募
不适用
Evaluate the Efficacy and Safety of Glaucoma Implant in Primary Open Angle GlaucomaGlaucomaNCT05892185Mingche Biotechnology CO., LTD20
已完成
不适用
MINIject Glaucoma Implant in European PatientsGlaucoma, Open-AngleGlaucoma EyeIntraocular PressureNCT03624361iSTAR Medical29
Unknown
不适用
Evaluation of Performance and Safety of Eye Drops With Hydroxypropyl-methylcellulose and Inositol in Drye Eye DiseaseDry Eye Disease Associated to Asthenopia and Accommodative Effort in Video Display Terminal UsersNCT06190054Fidia Farmaceutici s.p.a.100
终止
不适用
Multicenter Ab-interno Glaucoma Study Investigating CanaloplastyPrimary Open Angle GlaucomaNCT04769453Nova Eye, Inc.20